Use of Saliva to Identify Varicella Zoster Virus Infection of the Gut

Anne A. Gershon,1 Jason Chen,2 and Michael D. Gershon2

Departments of 1Pediatrics, and 2Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, New York

Background.
Varicella zoster virus (VZV) establishes latency in dorsal root, cranial nerve, and enteric ganglia and can reactivate to cause zoster. Serious gastrointestinal dysfunction can result from VZV reactivation in enteric neurons (enteric zoster), but an absence of rash makes diagnosis difficult. We thus determined whether detecting VZV DNA in saliva facilitates identification of enteric zoster.

Methods.
Nested and real-time polymerase chain reaction were used to validate salivary VZV DNA as a surrogate marker of VZV reactivation and then to determine the utility of that marker for the identification of those individuals within a population defined by abdominal pain that might have enteric zoster.

Results.
Salivary VZV DNA was detected in 0 of 20 healthy negative controls, 11 of 16 positive controls with zoster or varicella (P < .0001), 2 of 2 patients with zoster sine herpete (P < .01), 6 of 11 patients with unexplained abdominal pain (P < .001), and 0 of 8 patients with unrelated gastrointestinal disorders. Salivary VZV DNA disappeared after recovery in 9 of 9 tested subjects with zoster, 2 of 2 with zoster sine herpete, and 5 of 5 with abdominal pain. One patient with abdominal pain and salivary VZV DNA had perforated gastric ulcers, necessitating a wedge gastrectomy. VZV DNA (vaccine type) was found in the resected stomach; immediate early (ORF63p) and late (gE) VZV proteins were immunocytochemically detected in gastric epithelium. After recovery, VZV DNA and proteins were not detected in gastric biopsies or saliva.

Conclusions.
Detection of salivary VZV DNA in patients with abdominal pain helps to identify putative enteric zoster for investigation and treatment.

Keywords. abdominal pain; bleeding peptic ulcer; enteric infections; enteric neurons; enteric nervous system.
consistently been found in patients with clinical zoster [12] but not in healthy subjects [13]. These observations suggest that salivary VZV DNA is a biomarker of active VZV infection, whether or not there is a cutaneous accompaniment. The current investigation was undertaken to test the hypothesis that VZV DNA in saliva can be used to identify patients with gastroenterologically unexplained GI symptoms who are likely to have enteric zoster.

METHODS

Patients
Columbia University’s Institutional Review Board approved this investigation. Saliva was obtained from 5 groups of subjects. The first group, healthy volunteers, was a negative control. The second group of patients with a characteristic rash clinically diagnosed as varicella or zoster served as a positive control; polymerase chain reaction (PCR) detected VZV DNA in cutaneous lesions. Saliva was collected during and after acute infection. Postrecovery saliva served as each patient’s internal control. The third group consisted of patients with zoster sine herpete; saliva was collected both during the symptomatic illness and after recovery. The fourth group, candidates for enteric zoster, were referrals from a gastroenterologist for unexplained GI illness with moderate to severe abdominal pain; saliva was collected while symptoms were present and after recovery. Severe bleeding from perforated gastric ulcers in 1 patient necessitated surgical intervention. The affected bowel contained VZV DNA, transcripts, and protein. The fifth group consisted of patients with a long-standing GI disorder unrelated to VZV (see Supplementary materials for additional details).

Collection and Processing of Specimens
Saliva was collected with OriGene-Discover kits (Ottawa, Canada) or on swabs placed in the mouth for approximately 3 minutes. Swabs were subsequently soaked in sterile water and stored in buffer (50 mM Tris, pH 8.0, 1 mM ethylenediaminetetraacetic acid, 0.1% sodium azide) at 4°C. DNA was extracted with DNeasy Blood and Tissue Kit (Qiagen, Valencia, California).

PCR Analysis of VZV DNA
Four methods were employed to distinguish wild-type (WT) from vaccine-type (vOka) VZV DNA: (1) Differences between circulating US/UK WT VZV and the Asian-derived (clade 2) vOka were used to screen samples [14]. PCR amplified, in gene 54, a 222-bp region that includes a BglII restriction site and, in gene 38, a 350-bp region that contains a PsI restriction site. The PsI restriction site is present in circulating Western strains but not in vOka. In contrast, vOka contains a BglII restriction site, which is present only in approximately 20% of Western strains. (2) To confirm vOka, a region containing a vOka-unique SmalI restriction site in open reading frame (ORF) 62 was amplified to yield a specific 268-bp amplicon [15–17]. Digestion of WT strains, which contain 2 Smal restriction sites, produces 153-, 79-, and 36-bp fragment sets, whereas vOka, which contains 3 Smal restriction sites, produces 112-, 79-, 41-, and 36-bp fragment sets. For final confirmation, the 268-bp amplicon was sequenced. WT VZV has a thymine at 106262, whereas vOka has a cytosine [18]. (3) Nested PCR was used to analyze ORFs 29, 31, 67, 40, or 68 in saliva where the abundance of VZV DNA is low [1]. The sensitivity of this assay, determined by serial dilution of plasmid-derived fragments, was 1–2 copies. (4) Real-time PCR was used to confirm nested PCR results. The single-nucleotide polymorphism (SNP) at 106262 of ORF62 was analyzed; sensitivity was 2–4 copies (see Supplementary materials for additional details).

Immunocytochemistry
Formalin-fixed, paraffin-embedded sections were exposed, after antigen retrieval at 100°C in citrate buffer (pH 6.0), to rabbit ORF62p antibodies [19] and monoclonal glycoprotein E (gE) antibodies (Virusys Corp, Taneytown, Maryland). Primary antibodies were omitted as a control. Alexa 488- and 594-conjugated secondary antibodies (against rabbit or mouse immunoglobulin G) (Molecular Probes, Eugene, Oregon) were used to visualize immunoreactivity. Nuclei were stained with bisbenzimide (Sigma-Aldrich, St Louis, Missouri) (see Supplementary materials for additional details).

RESULTS
Saliva from 54 individuals was studied. Salivary VZV DNA was not detected in any of the 20 individuals in group 1 (the negative controls), who manifested neither pain nor rash. Salivary VZV DNA was detected in 11 of 16 subjects in group 2 (the positive controls), who manifested neither pain nor rash. Neither of the 2 patients in group 3 (zoster sine herpete), manifested rash, GI symptoms, or abdominal pain; however, both had severe unilateral cutaneous pain and hyperesthesia in a dermatomal distribution. Salivary VZV DNA, collected while pain was present, was detected in 2 of 2 patients (P < .01 vs control; Figure 1B) and disappeared in each person after recovery (Table 2). The 11 subjects in group 4, possible enteric zoster, were referred by gastroenterologists because moderate to severe abdominal pain up to 4 months’ duration could not be explained; none had a rash. Salivary VZV DNA was detected in 6 of 11 (Figure 1C; 55%; P < .001 vs control; Table 2, patients
The case of 1 patient from group 4, which is particularly noteworthy because it demonstrates that vOka can cause enteric zoster, has been reported to the Worldwide Adverse Experience System and to the US Food and Drug Administration. This subject was a 16-year-old African American male with a history of asthma and obesity who suddenly experienced severe epigastric abdominal pain, lost consciousness, and was hospitalized. An emergency laparotomy was undertaken after abdominal radiography revealed free air under the diaphragm. Multiple necrotic ulcers were found in the gastric fundus. A wedge gastrectomy was performed to remove the affected stomach along with an adjoining necrotic portion of greater omentum. Antibodies to neither Helicobacter pylori nor herpes simplex virus were detected in serum, and the gastrin level was normal. Immunoglobulin levels and numbers of circulating CD4, CD8, and natural killer cells were also normal. Abdominal pain and a fever persisted after surgery. Respiratory failure requiring intubation occurred and aspiration pneumonia was identified. Systemic bacterial infection was suspected; nevertheless, despite multiple cultures, no pathogens were identified. Medications administered during the patient’s month-long hospitalization included vancomycin, ciprofloxacin, metronidazole, and fluconazole. At no time did the patient manifest a rash.

The patient’s saliva, analyzed 2 weeks after the onset of illness, was found to contain DNA encoding VZV ORFs 40 and 67 (Figure 2A). VZV DNA was then found to be present in the resected stomach (Figure 2B). SmaI restriction analysis and sequencing of position 106262 of ORF62 identified the viral DNA vOka-derived [17]. Gastric mucosal ulceration, hemorrhage, and inflammation were found microscopically (Figure 2C). Intact neurons were not encountered in the expected region of the myenteric plexus (Figure 2D), despite examination of multiple sections and immunostaining with antibodies to the neuronal marker PGP9.5 (data not shown). A mononuclear cell infiltrate and areas of hemorrhage were present between muscle bundles. Many ORF63p- and gE-immunoreactive cells were present in the epithelium of gastric glands and lamina propria adjacent to mucosal ulcers. ORF63p and gE immunoreactivities were coexpressed (Figure 3A1–A6). No immunoreactivity was found when antibodies to gE or ORF63p were omitted (Figure 3B1–B6). The patient recovered without antiviral therapy. At the time of discharge, VZV DNA could no longer be detected in saliva and the patient was free of abdominal pain; nevertheless, difficulty swallowing, diagnosed clinically as achalasia, remained. Further diagnostic testing was refused. Saliva was free of VZV DNA 3 weeks after discharge, when the gastric mucosa was found endoscopically to be normal and mucosal biopsies contained no detectable VZV DNA; moreover, immunocytochemical examination of biopsied tissue revealed no immunoreactivities of gE or ORF63p (Figure 4A1–A6).

3–8). Three patients recovered after treatment with valacyclovir, and 3 recovered without treatment. Importantly, salivary VZV DNA was no longer present in 5 of 5 samples obtained after abdominal pain disappeared. The 8 patients in group 5 had pain from a chronic GI disease unrelated to VZV. Five had gastrointestinal reflux, 2 had idiopathic gastroparesis, and 1 had chronic intestinal pseudo-obstruction. Salivary VZV DNA was detected in 0 of 8.

**Figure 1.** Frequency of salivary varicella zoster virus (VZV) DNA in saliva of negative control (healthy) subjects, positive control (zoster/varicella) subjects, patients with zoster sine herpete, and patients with unexplained abdominal pain (without rash). A $\chi^2$ analysis of the overall distribution (zoster/varicella and zoster sine herpete groups combined) was significantly different from chance ($P < .0001$). A, The difference in frequency between the detection of salivary VZV DNA in the positive control population is significantly greater than that in the negative control population. Fisher exact test. B, The difference in frequency between the detection of salivary VZV DNA in patients with zoster sine herpete is significantly greater than that in the negative control population. Fisher exact test. C, The difference in frequency between the detection of salivary VZV DNA in the group of patients with unexplained abdominal pain is significantly greater than that in the negative control population. Fisher exact test.
DISCUSSION

The current study supports the utility of salivary VZV DNA as an indicator of enteric zoster. We first confirmed that our methods did not detect VZV DNA in the saliva of healthy, non-stressed, asymptomatic adults (0/20). In contrast, we detected VZV DNA in the saliva of 11 of 16 subjects clinically diagnosed with zoster or varicella. The difference in salivary VZV DNA between the positive and negative control populations was highly significant ($P < .0001$). VZV also disappeared from saliva upon recovery in 9 of 9 positive control subjects from whom convalescent samples were obtained. Salivary VZV DNA has been reported in a numerically greater, but not significantly different, proportion of cases of varicella [21] than found in our study, predominantly of zoster. VZV DNA may be more readily detected in vesicles than in saliva; nevertheless, when skin

<p>| Table 1. Varicella Zoster Virus DNA in Saliva: Otherwise Healthy Patients With Varicella or Zoster |
| Stop line |</p>
<table>
<thead>
<tr>
<th>Patient Information</th>
<th>VZV DNA Skin</th>
<th>VZV DNA Acute Saliva</th>
<th>VZV DNA Convalescent Saliva</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Age, y</td>
<td>Description</td>
<td>Positive (vOka)</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>Rash left arm, axilla</td>
<td>Positive</td>
</tr>
<tr>
<td>Female</td>
<td>17</td>
<td>Lymphoma; unilateral rash</td>
<td>Positive</td>
</tr>
<tr>
<td>Male</td>
<td>23</td>
<td>Rash on left back and shoulder</td>
<td>Not tested</td>
</tr>
<tr>
<td>Female</td>
<td>35</td>
<td>Painful, faint rash on left thorax</td>
<td>Positive</td>
</tr>
<tr>
<td>Female</td>
<td>40</td>
<td>Unilateral rash on face</td>
<td>Positive</td>
</tr>
<tr>
<td>Female</td>
<td>43</td>
<td>Itchy rash on left back</td>
<td>Positive</td>
</tr>
<tr>
<td>Female</td>
<td>43</td>
<td>Painful rash on left chest</td>
<td>Positive</td>
</tr>
<tr>
<td>Male</td>
<td>47</td>
<td>Painful rash on left cheek near eye; severe headache</td>
<td>Positive</td>
</tr>
<tr>
<td>Malea</td>
<td>50</td>
<td>Nurse with varicella; generalized vesicular rash, fever</td>
<td>Positive (WT)</td>
</tr>
<tr>
<td>Female</td>
<td>50</td>
<td>Painful rash left neck</td>
<td>Positive (WT)</td>
</tr>
<tr>
<td>Female</td>
<td>55</td>
<td>Painful red maculopapular rash on left back and shoulder</td>
<td>Not tested;</td>
</tr>
<tr>
<td>Maleb</td>
<td>60</td>
<td>Painful rash left arm</td>
<td>Positive (WT)</td>
</tr>
<tr>
<td>Male</td>
<td>60</td>
<td>Rash left axilla and back</td>
<td>Positive</td>
</tr>
<tr>
<td>Female</td>
<td>61</td>
<td>No skin rash, but vesicles in larynx</td>
<td>Not tested</td>
</tr>
<tr>
<td>Female</td>
<td>71</td>
<td>5 small vesicles left wrist</td>
<td>Positive (WT)</td>
</tr>
<tr>
<td>Male</td>
<td>88</td>
<td>Rash on left forehead</td>
<td>Not tested</td>
</tr>
</tbody>
</table>

Rows in italics refer to a cluster of subjects working in a varicella zoster laboratory.

Abbreviations: vOka, live attenuated strain of varicella zoster virus; VZV, varicella zoster virus; WT, wild type.

a | Varicella.

b | Asian immigrants to United States, VZV clade 2 [20].

<p>| Table 2. Varicella Zoster Virus DNA in Saliva: Patients Without Skin Rash |
| Stop line |</p>
<table>
<thead>
<tr>
<th>Patient Information</th>
<th>VZV DNA Acute Saliva</th>
<th>VZV DNA Convalescent Saliva</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Age, y</td>
<td>Description</td>
</tr>
<tr>
<td>Male</td>
<td>16</td>
<td>Severe pain, left chest, torso zoster sine herpete</td>
</tr>
<tr>
<td>Male</td>
<td>72</td>
<td>Severe pain right chest, back, shoulder zoster sine herpete</td>
</tr>
<tr>
<td>Male</td>
<td>6</td>
<td>Severe abdominal pain-response to valacyclovir</td>
</tr>
<tr>
<td>Malea</td>
<td>16</td>
<td>Vaccinated—abdominal pain, GI bleeding, and perforated gastric ulcer</td>
</tr>
<tr>
<td>Male</td>
<td>27</td>
<td>Severe abdominal pain</td>
</tr>
<tr>
<td>Female</td>
<td>30</td>
<td>Severe abdominal pain; Helicobacter pylori negative; response to valacyclovir</td>
</tr>
<tr>
<td>Female</td>
<td>55</td>
<td>Severe abdominal pain</td>
</tr>
<tr>
<td>Malea</td>
<td>60</td>
<td>Severe abdominal pain; H. pylori negative; response to valacyclovir</td>
</tr>
</tbody>
</table>

Patients noted in italics work in a VZV laboratory.

Rows in italics refer to a cluster of subjects working in a varicella zoster laboratory.

Abbreviations: GI, gastrointestinal; vOka, live attenuated strain of varicella zoster virus; VZV, varicella zoster virus; WT, wild type.

a | Patient in case report.
lesions are absent, salivary VZV DNA may be required to confirm VZV infection [22]. Salivary VZV DNA and its disappearance after recovery, for example, provided our only laboratory confirmation of zoster sine herpete.

We used persistent abdominal pain, which was unexplained by a gastroenterological workup, to screen subjects for possible enteric zoster. VZV DNA was present in the saliva of 6 of 11 (55%) subjects, which differed significantly from the negative control population (0/20; \( P < .0001 \)). Salivary VZV DNA was no longer detectable in any of 5 individuals after pain disappeared, either in apparent response to valacyclovir (3/5) or spontaneously (2/5). These observations are consistent with the hypothesis that salivary VZV DNA helps detect enteric zoster and monitor its therapy. In fact, given the nonspecific nature of unexplained abdominal pain, the proportion of subjects with salivary VZV DNA is surprisingly large. No salivary VZV DNA was detected in subjects with gastroesophageal reflux or other chronic GI disorders, suggesting that the stress of GI dysfunction is not, by itself, sufficient to cause VZV DNA to appear in saliva.

We conclude that salivary VZV DNA is a surrogate marker of active VZV infection, which can, in the presence of abdominal pain, suggest enteric zoster. The internal nature of enteric zoster, in which cutaneous manifestations are absent, would otherwise necessitate an invasive procedure to obtain tissue for diagnosis. VZV reactivation as a cause of disease without rash was, until recently, thought to be rare or nonexistent. It is now clear that this is not the case [2,23]; meningitis, myelitis, and zoster sine herpete are examples [24]. VZV establishes latency in nodose [25], celiac [25], and enteric neurons [26], which project to the gut but not to the skin. Subsets of each innervate the mucosa [27]; therefore, reactivation of VZV in these enteric-projecting neurons would be expected, because of axonal transport, to deliver infectious VZV to the bowel and the mucosal epithelium [27]. VZV-induced mucosal damage would be expected to cause GI ulceration, bleeding.

Figure 2. Varicella zoster virus (VZV) infection was detected in saliva and resected stomach from a patient with abdominal pain, bleeding, and perforated gastric ulcer. A, DNA from saliva amplified with polymerase chain reaction. DNA encoding open reading frame (ORF) 40 and ORF67 was amplified in the patient’s saliva (Pt) and in the positive control DNA prepared from a plasmid (+) but not in the negative control (−). B, The genotype of the viral DNA from resected stomach is that of vOka. DNA was digested with the Pst1 restriction endonuclease. C, Low-power micrograph showing the ulcerated mucosa of the patient’s resected stomach. This is the region of the stomach from which DNA was extracted. Hematoxylin and eosin (H&E) stain; scale bar = 100 μm. D, Muscularis of the stomach. The myenteric plexus is not evident. H&E stain; scale bar = 100 μm. Abbreviations: M, size marker; Pt, DNA extracted from the resected stomach of the patient; vOka, DNA extracted from cells infected with vOka; WT, DNA extracted from cells infected with wild-type VZV (Dumas).
and pain. Even if a reactivated enteric VZV infection were to be confined to enteric ganglia, the resulting neuronal dysfunction would disturb GI motility/secretion, leading to intestinal distension and abdominal pain.

Saliva, in which DNA is abundant, can be obtained easily and noninvasively. The appearance of VZV DNA in the saliva of highly stressed individuals, such as astronauts [9] or hospitalized children in intensive care [28], occurred in the absence of overt disease and was, therefore, due to subclinical reactivation of VZV. Moreover, the appearance of VZV DNA in saliva of patients with obvious zoster supports the idea that salivary VZV DNA accurately reflects the presence of active VZV infection [12, 22]. A genomic study showed that in patients with varicella, saliva and skin contained identical VZV clades, suggesting that salivary VZV DNA was derived from the rash-causing virus [21]. If salivary VZV DNA is due to a

**Figure 3.** The immunoreactivity of the varicella zoster virus proteins glycoprotein E (gE) and open reading frame (ORF) 63p are present and can be detected immunocytochemically in the mucosa of the resected stomach. A1–A6. The same field is shown in all 6 panels, illuminated to demonstrate the fluorescence of DNA (A1), gE (A3), and ORF63 (A5) as well as an interference contrast image of the mucosa (A4), the merged image of DNA + gE + ORF63 (A6), and the merged fluorescence and interference contrast images (A5). Note that the immunofluorescence of gE and ORF63 are coincident in the mucosa and are found in epithelial cells, underlying stromal cells of the lamina propria, and some mucosal blood vessels (linear structures). B. Control immunoreactivity. The primary antibodies to gE and ORF63p were omitted, but the sections were processed as in A. B1–B6. Again, a single field is illustrated in all 6 panels, illuminated to demonstrate the fluorescence of DNA (B1), gE (B2), ORF63 (B3), an interference contrast image (B4), the merged image of DNA + gE + ORF63 (B5), and the merged fluorescence and interference contrast images (B6). No green or red fluorescence can be detected. Scale bars = 50 µm.
subclinical reactivation that boosts immunity, its detection may clinically be inconsequential. In contrast, if salivary VZV DNA reveals that a symptomatic condition is due to VZV, as in patients with unexplained abdominal pain and GI dysfunction, its detection may allow antiviral treatment to be initiated in time to provide relief.

The nearly catastrophic case of a 16-year-old boy illustrates the utility of testing saliva to detect enteric zoster. The patient experienced not just abdominal pain, but also gastric ulceration and perforation, necessitating a wedge gastrectomy. The discovery of salivary VZV DNA was, in fact, what caused the resected gastric tissue to be analyzed for VZV. That analysis subsequently revealed VZV DNA in the stomach, identified the DNA as vOka-derived, and revealed that the mucosal epithelium and lamina propria along ulcer borders contained gE and ORF63p immunoreactivities. Because the individual had previously received 2 doses of varicella vaccine, it is likely that vOka reactivated from latency in enteric neurons. The absence of ganglia in the resected stomach is consistent with this idea and suggests that the neurons in which VZV reactivated did not survive. The patient was left with a residual swallowing problem. In an in vitro guinea pig model, latently infected enteric neurons die 48–72 hours after VZV reactivation [29]. The immunocytochemical detection of both early and late proteins indicated that VZV was proliferating in gastric mucosa at the time of resection and thus was probably the source of the VZV DNA in saliva. After recovery, when bleeding and pain had disappeared, VZV could no longer be found in mucosal biopsies, and salivary VZV DNA also disappeared. Unfortunately, the family did not agree to further testing to identify an underlying immunological deficit, such as natural killer cell function [30–32], that might explain the reactivation of vOka or the severity of enteric zoster.

The vOka strain has previously been reported to cause latency and zoster, albeit at a lower frequency than that of WT VZV [33]. Millions of doses of varicella vaccine have been distributed since its approval in 1995; nevertheless, gastric ulcer has not previously been reported as a complication of vaccination and must therefore be rare. In contrast, zoster and postherpetic neuralgia are commonly observed in patients with gastric ulcer disease [34]; this correlation is consistent with the idea that enteric reactivations of VZV may occur together with, or predispose to, VZV reactivations in dorsal root ganglia or cranial nerve ganglia.

Zoster in 2 subjects, who experienced childhood varicella in China, was due to a clade 2 VZV (WT, not vOka), which is common in Asia but rare in the West. Unexpectedly, 6 of 16 (38%) subjects with zoster in the current study worked in a laboratory where VZV is investigated. The incidence of zoster encountered in this population (100 per 1000 person-years) is very high. The incidence of zoster in the placebo group of a recent study of fingolimod was 6 per 1000 person-years, and that in patients treated with fingolimod was 11 per 1000 person-years.
The chance of experiencing zoster has recently been estimated to be about 30% over a lifetime [36]. Because exposure to VZV causes varicella rather than zoster in susceptible individuals, the apparent cluster of zoster in a VZV laboratory is probably due to awareness and availability of diagnostic tools. Zoster may thus be more common than currently supposed and might be diagnosed more frequently if the index of suspicion were higher. The relative ease of detection of salivary VZV DNA may therefore increase identification of treatable patients. It is also possible that asymptomatic reactivation of VZV in the GI tract and occurrences of enteric zoster boost immunity to VZV, thereby facilitating long-term protection against subsequent illness [37, 38].

Still to be determined is whether the presence of VZV DNA in the saliva of patients with abdominal pain is, by itself, sufficient to make a diagnosis of enteric zoster. Severe stress alone may be associated with the appearance of VZV DNA in saliva [9]; conceivably, therefore, the stress of an underlying GI illness might reactivate VZV in the gut or elsewhere. Salivary VZV DNA, however, was not found in patients with chronic GI disorders unrelated to VZV. The observations, moreover, that salivary VZV DNA disappeared in apparent response to valacyclovir in 3 patients and in all patients after their unexplained abdominal pain relented is consistent with the supposition that the abdominal pain resulted from enteric zoster. Although zoster commonly occurs in patients with inflammatory bowel disease, this comorbidity is probably due to the underlying immunological defect and/or immunosuppressive therapy [39]. Endoscopic or surgical confirmation of enteric zoster and its course will be needed in the future; however, the current work suggests that salivary VZV DNA can be used to select patients for treatment and appropriate investigation. Further studies are also needed to determine whether episodes of enteric zoster act as an unsuspected initiator of idiopathic GI disorders, such as postinfectious irritable bowel syndrome, gastroparesis, and intestinal pseudo-obstruction.

**Supplementary Data**

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**

**Acknowledgments.** The authors thank Kara Gross Margolis, MD, Anne Pierog, MD, Christina Gagliardo, MD, and Sruiti Nadimpali, MD, for help with patients, and Yan Zhou, Sharon Steinberg, Alexander Diacou, and Dong Wu, PhD, for their laboratory assistance.

**Financial support.** This work was supported by the National Institutes of Health (grant number DK093094).

**Potential conflicts of interest.** A. A. G. has received institutional support through the following companies: consulting honorarium from Pfizer, review board activities for GlaxoSmithKline, and a laboratory diagnostic service contract from Merck for safety of VZV vaccines. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**


Identification of Enteric Zoster • CID 2015;61 (15 August) • 543


